报价延迟最少15分钟:2026/06/22 07:15 EDT
盘前时段
|
||||
|
21.36 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
22
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.62/--
|
|
企业价值
--
|
| 资产负债 |
|
每股账面净值
不适用
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a singleoperating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease. |
